PREVIOUS EPISODE
<h2>Polyp Gossip Episode 3: Living with CRSwNP: Daily Challenges and Solutions</h2>

In this episode of Polyp Gossip, we dive into the real-life experiences of patients living with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), exploring how the condition impacts their daily routines, relationships, and overall well-being. Our guests share their journeys, shedding light on the emotional and physical toll of the condition.

Surgical Whispers: is One Surgery Enough Before Biologics?

Scent-sational Secrets: The Smell Loss Truth

<h2>Biography</h2>
<h3>Wytske Fokkens</h3>
Wytske J. Fokkens, MD, PhD, is a Professor at the Department of Otorhinolaryngology at the Academic Medical Center in Amsterdam. She is the Director of the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) Innovation Forum, Chairperson of the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS), and a member of the European Rhinologic Society Foundation Committee.&nbsp;
Prof. Fokkens is a founding member of EUFOREA, member of the Allergic Rhinitis and its Impact on Asthma Initiative, which develops guidelines for the management of concurrent allergic rhinitis and asthma, and center leader for the Global Allergy and Asthma European Network, a consortium of leading European research centers specializing in allergic diseases. She received the 2015 Paul Ehrlich Award for Experimental Research from the European Academy of Allergy and Clinical Immunology (EAACI) in 2015 and is an honorary member of EAACI, the Spanish and Greek Societies of Otorhinolaryngology, and the Romanian Rhinologic Society.&nbsp;
Prof. Fokkens is the author of more than 500 peer-reviewed papers on allergy and rhinology. Her main field of interest is sinus surgery and mucosal pathology of the upper and lower airways. She has written a textbook on rhinology and skull base surgery and has led an advanced sinus surgery course for more than 15 years. She serves as Editor-in-Chief of&nbsp;Rhinology&nbsp;and Associate Editor of&nbsp;Allergy.
<h3>Peter Hellings</h3>
Peter W. Hellings, MD, PhD, is a Professor and Clinic Head at the Department of Otorhinolaryngology at the University Hospitals of Leuven, and a Guest Professor at Ghent University, Belgium.
Prof. Hellings' research has led to novel insights into the pathophysiology of allergy and chronic airway inflammation, with over 350 scientific publications in top journals in the field of allergology, rhinology, and respiratory care. He is the founder of the European Forum for Research and Education in Allergy and Airway Diseases, an international nonprofit involving a consortium of European key opinion leaders aiming at the implementation of optimal care for chronic respiratory diseases. He is also the founder and director of the European Rhinoplasty Course and a member of European and American guideline committees.

Heeft u vragen of wilt u meer weten? Wij zorgen dat u zo snel mogelijk geholpen wordt.

Wij staan klaar

In this episode of Polyp Gossip, we dive into the real-life experiences of patients living with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), exploring how the condition impacts their daily routines, relationships, and overall well-being. Our guests share their journeys, shedding light on the emotional and physical toll of the condition.

Polyp Gossip – Episode 3

CHRONIC-RHINOSINUSITIS-WITH-NASAL-POLYPS-CRSWNP

RESPIRATORY

PREVIOUS EPISODE
<h2>Polyp Gossip – Episode 2: Scent-sational Secrets: The Smell Loss Truth</h2>

We explore the impact of smell impairment and its connection to CRSwNP. Featuring insights from our hosts and a special guest, we uncover pathways to recovery and improved quality of life.

Living with CRSwNP: Daily Challenges and Solutions

We explore the impact of smell impairment and its connection to CRSwNP. Featuring insights from our hosts and a special guest, we uncover pathways to recovery and improved quality of life.

Polyp Gossip – Episode 2

THE LATEST EPISODE
<h2>Polyp Gossip Episode 4: To Cut Or Not To Cut</h2>

In this episode we explore the critical decision of whether surgery is the right choice for CRSwNP patients. Leading experts discuss the factors influencing surgical vs. medical management, patient considerations, and the latest advancements in treatment. Tune in for an in-depth look at this big decision in CRSwNP care!

Polyp Gossip is a video podcast dedicated to exploring Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). Hosted by two globally recognized rhinologists. The show delves into trending topics, latest advancements, and patient experiences. Each episode features esteemed guests, including experts and patients, offering valuable insights into the evolving world of CRSwNP.

Polyp Gossip

PREVIOUS EPISODE
<h2>Polyp Gossip – Episode 1: Surgical Whispers: Is One Surgery Enough Before Starting Biologics?</h2>

Welcome to the debut episode of Polyp Gossip! In this episode, our expert panel explores a critical question in CRSwNP management: Is one surgery enough before starting biologics?

Welcome to the debut episode of Polyp Gossip! In this episode, our expert panel explores a critical question in CRSwNP management: Is one surgery enough before starting biologics?

Polyp Gossip – Episode 1

March 13th 2024, Brussels

Watch the interview from Rhino Rounds International 2024 in Brussels where Prof. Hellings and Dr. Reitsma discuss, diagnosis and management of CRSwNP, treatment options and surgical intervention, comorbidities and follow-up care.

<h4>Disclosures/conflict of interest:</h4>
Prof. Peter Hellings has received speaker fees and/or unrestricted research grants from the following: ALK, GSK, Sanofi/Regeneron, Novartis, Stallergens and Viatris/Mylan.
Dr. Sietze Reitsma has received speaker fees and/or unrestricted research grants from the following:
<ul>
 <li>
 The department of othorhinolaryngology and head/neck surgery of Amsterdam UMC has received funding from Sanofi/Regeneron, Novartis and GSK.</li>
 <li>
 Dr. Reitsma is also board member of the steering committee of PolyREG, the Dutch national registry for biologics in CRSwNP, co-sponsored by Sanofi/Regeneron, Novartis and GSK.</li>
 <li>
 Dr. Reitsma also acted as consultant for Sanofi/Regeneron, Novartis, GSK and Boehringer Ingelheim.</li>
</ul>

Peter W. Hellings is a Professor in Otorhinolaryngology at the Catholic University of Leuven, Belgium, and Clinic Head at the Department of Otorhinolaryngology at the University Hospitals of Leuven. He is also a former Professor at the University of Amsterdam, The Netherlands, and a Guest Professor at the University of Ghent, Belgium. Following his speciality training and doctoral thesis in 2001, he combined clinical work in the field of rhinoplasty and sinus surgery, with the guidance of several PhD fellows in research on airway immunology, allergology, sinus disease and rhinoplasty. His scientific work is published in over 275 scientific reports and has been awarded several international prizes. He is the course director of the&nbsp;<a href="https://www.europeanrhinoplastycourse.eu/" style="color:blue; text-decoration:underline">European Rhinoplasty Course in Brussels</a>&nbsp;and the&nbsp;<a href="https://www.rhinoplastycourse.nl/" style="color:blue; text-decoration:underline">International Course in Modern Rhinoplasty Techniques Amsterdam</a>&nbsp;and the past-Secretary-General of EAACI (2015-2019). In 2015, he founded the non-profit organization EUFOREA aiming at arresting the epidemics of chronic respiratory diseases (CRD) in Europe via digital solutions and structural collaboration with relevant stakeholders in the field of CRD. At the occasion of the National Day in 2016, King Filip of Belgium granted him the title of Commander in the Order of Leopold.

Dr. Reitsma is an ENT physician at the Amsterdam UMC and is a globally recognized leader in Chronic Rhinosinusitis with Nasal Polyposis and sinus and skull base surgery with more than 85 research publications. His expertise lies in understanding mucosal pathology in the upper and lower airways, with a particular focus on precision medicine. Dr. Reitsma's research encompasses diverse areas such as quality of life assessments, treatment outcomes, and economic considerations, aiming to improve patient care on individual and societal levels. A distinguishing aspect of Dr. Reitsma's work is his exploration of treatable traits and endotyping within CRSwNP. Through a combination of basic immunological research, epidemiological studies, and clinical trials, he seeks to uncover the underlying mechanisms of this condition and develop personalized treatment approaches.

WATCH THE FULL EVENT OF RHINO ROUNDS INTERNATIONAL 2024

Rhino Rounds International 2024 - Interview

<h2>Rhino Rounds International 2024 – Moving forward in CRSwNP</h2>
<h4>March 13th 2024, Brussels</h4>
Watch the full video from Rhino Rounds International 2024 in Brussels where Prof. Hellings and Dr. Reitsma sharing insights on the latest advancements in CRSwNP and discussing the future of biologic treatments.

Rhino Rounds International 2024

<h2>PubExplainer Dupilumab LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52</h2>
In de fase 3-studies&nbsp;LIBERTY NP SINUS-24 en LIBERTY NP SINUS-52&nbsp;zijn veiligheid en effectiviteit van dupilumab, toegevoegd aan standaardbehandeling, bij patiënten met ernstige chronische rhinosinusitis met neuspoliepen geëvalueerd.1&nbsp;
In deze video komen achtereenvolgens kort en bondig studie-opzet, uitkomsten op primaire en secundaire eindpunten en verdraagbaarheid aan bod.
Bent u KNO-arts? Dan mag u deze video niet missen! Uiteraard is deze video ook te bekijken door andere geïnteresseerde zorgprofessionals zoals huisartsen.

<h2>Bekijk de PubExplainer Dupilumab LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52 door op de video te klikken</h2>

Kom meer te weten over de achtergronden en belangrijkste uitkomsten van de LIBERTY NP SINUS-52 and LIBERTY NP SINUS-24-studies.

<h2>Samenvatting en uitkomsten</h2>
Uit de fase 3-studies LIBERTY NP SINUS-24 en LIBERTY NP SINUS-52 bleek dat dupilumab een effectieve en goede verdraagbare aanvullende behandeling is bij ernstige chronische rhinosinusitis met neuspoliepen.1

De belangrijkste kenmerken en uitkomsten van deze studies:
<ul>
 <li>LIBERTY NP SINUS-24: randomisatie naar ofwel aanvullende behandeling met dupilumab elke 2 weken ofwel placebo gedurende 24 weken met een follow-up van 24 weken</li>
 <li>LIBERTY NP SINUS-52: randomisatie naar aanvullende behandeling met dupilumab elke 2 weken gedurende 52 weken ofwel dupilumab elke 2 weken gedurende de eerste 24 weken met switch naar dupilumab elke 4 weken voor de daaropvolgende 24 weken plus follow-up van 12 weken, ofwel placebo elke 2 weken gedurende 52 weken.</li>
</ul>

Dupilumab leidde tot:
<ul>
 <li>Significante en snelle reductie van neuspoliepscore en neuscongestie/-obstructie in week 24</li>
 <li>Significant verminderd gebruik van systemische corticosteroïden in week 52 t.o.v. placebo&nbsp;</li>
 <li>Minder benodigde sino-nasale chirurgie in week 52 t.o.v. placebo</li>
 <li>Verbeterde longfunctie en astmacontrole bij astmapatiënten in week 24</li>
 <li>Signifcante en snelle aanhoudende verbetering reukvermogen en gezondheidsgerelateerde kwaliteit van leven.</li>
</ul>

De meest voorkomende bijwerkingen werden vaker gezien in de placebogroep dan in de dupilumabgroep.

Op zoek naar meer informatie over de behandeling van chronische rhinosinusitis met neuspoliepen?&nbsp;<a href="https://www.mednet.nl/nascholing/" rel="noreferrer" target="_blank">www.mednet.nl</a>

In deze PubExplainer worden de uitkomsten van de fase-3 studies LIBERTY SINUS 24 &amp; 25 besproken. Hierin wordt dieper ingegaan op de effecitiviteit en veiligheid van dupilumab bij patiënten met ernstige chronische rhinosinusitis met neuspoliepen.

PubExplainer LIBERTY SINUS 24 & 52

Voor uw intercontext, meld u aan bij uw account Sanofi Campus. Geef uw e-mail door aan uw e-mail.

Als u onze eerste e-mail op {email} tot bevestig uw account u kunt hieronder een nieuwe aanvragen. Als je het niet ziet, moet je mogelijk je spammap controleren.

Deze informatie wordt alleen gebruikt om uw account te valideren en wordt niet verspreid.

titel

Title

This website is for healthcare professionals only.

Welcome to BP Sanofi Campus

Create new password

Om u een gepersonaliseerde ervaring te bieden, moet u

Je profiel is onvolledig

De ADCT geeft een indicatie van hoe gecontroleerd het eczeem is. Beantwoord deze 6 eenvoudige vragen met uw patiënt om de ADCT-score te vinden. Het zal de juiste handelwijze aangeven.

Atopische dermatitis, een vorm van eczeem, kan het leven van uw patiënt op meer manieren beïnvloeden dan u weet.

Doe de atopische dermatitis controle test (ADCT)

Geniet van meer exclusieve inhoud{newline}door <a>door u vandaag te registreren</a>

Heb je al een account? <a>Hier inloggen</a>

Best practices voor het optimaliseren van de patiëntenzorg

Krijg een aangepast beeld van de onderwerpen waarin u geïnteresseerd bent, samen met de mogelijkheid om inhoud op te slaan om op een later tijdstip te bekijken of te lezen.

Onbeperkte toegang tot eersteklas inhoud, whitepapers, casestudy's, onderzoekspapers, webinars, training en up-to-date wetenschappelijke medische bronnen.

Gepersonaliseerde inhoud op basis van uw interessegebieden

Maak contact en blijf up-to-date met collega's op uw vakgebied en onderwerpen die u interesseren via gratis evenementen en leidinggevende forums.

Registreer om het volledige artikel te lezen.

Wij respecteren uw privacy en zullen uw informatie niet delen met derden.

Actuele gidsen die speciaal voor patiënten zijn geschreven

Onbeperkte toegang tot de nieuwste patiëntengidsen en bronnen. Deel inhoud met uw patiënten met gebruiksvriendelijke online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Beperkte toegang

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

Normaal gesproken bieden we een schat aan kenis, maar we konden niet vinden waar je naar op zoek bent.

We konden niet vinden wat je zocht

Sanofi is niet verantwoordelijk voor de inhoud van deze externe website.

U staat op het punt Campus.sanofi/nl te verlaten.

Images from <a>iStockphoto.com</a>, Fotolia.de, <c>gettyimages.de</c>, <d>pexels.com</d> and <e>photocase.de</e> were used for our websites.

Volg ons:

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch. All fields are required.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

Sanofi biedt u exclusieve content over onze verschillende therapeutische gebieden op één portal speciaal voor professionals in de gezondheidszorg, inclusief wetenschappelijk nieuws, een lijst met evenementen en tools en diensten voor uw dagelijkse praktijk.

Bevestig uw status

De inhoud van deze website is alleen toegankelijk voor geregistreerde gebruikers.

Log in alstublieft

Email verificatie

U ziet een voorbeeld van de portal. Wis uw cookies (bijvoorbeeld door uw browservenster te sluiten) om terug te gaan naar de openbare modus.

We hebben onze privacyverklaring bijgewerkt om je gegevens beter te beschermen en je ervaring te verbeteren. Neem even de tijd om de wijzigingen door te nemen door <privacyNewTab>hier te klikken</privacyNewTab>. Uw privacy is belangrijk voor ons. Klik op doorgaan om te bevestigen dat u de nieuwe privacyverklaring hebt gelezen.

Update van de privacyverklaring

Communicatie toestemming

My consents

Password

Confirm password

{resultsCount, plural, one {resultaat} other {resultaten}}

Log in om toegang te krijgen tot de resultaten

U moet inloggen op uw account om toegang te krijgen tot medische inhoud.

Inloggen

Registreer in minder dan 1 minuut om toegang te krijgen tot de resultaten

U verlaat nu het Sanofi inhoudsgedeelte van onze site en komt in het inhoudsgedeelte voor extern medisch bibliografisch zoeken.

U verlaat nu het externe medische bibliografische zoekgedeelte van onze site en komt in het inhoudsgedeelte van Sanofi.

Chronische rinosinusitis met neuspoliepen (CRSwNP)

Educatie